Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Managed Health Care2.56%+0.64 ppPharmaceuticals5.04%+0.30 ppLife Sciences Tools & Services1.99%-0.29 ppHealth Care Equipment2.86%-0.23 ppBiotechnology2.39%-0.17 ppHealth Care Supplies0.16%-0.16 ppHealth Care Distributors0.40%+0.13 ppHealth Care Services0.91%+0.10 ppHealth Care Facilities0.20%-0.07 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.39%
Industry change · 12M
-0.17 pp
Biotechnology · contribution
-0.174 pp
Company participation
25%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Aug 2022 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Moderna → MRNA | United States | $51.7bn | 0.185% | -0.023 pp | -0.323 pp | -64.9% | No |
| AbbVie → ABBV | United States | $237.7bn | 0.851% | -0.087 pp | +0.137 pp | +15.9% | No |
| Vertex Pharmaceuticals → VRTX | United States | $72.3bn | 0.259% | +0.011 pp | +0.085 pp | +40.7% | Yes |
| Biogen → BIIB | United States | $28.4bn | 0.101% | -0.004 pp | -0.067 pp | -42.4% | No |
| Amgen → AMGN | United States | $128.5bn | 0.460% | -0.034 pp | +0.032 pp | +10.1% | No |
| Gilead Sciences → GILD | United States | $79.6bn | 0.285% | -0.008 pp | -0.020 pp | -8.8% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $54.6bn | 0.195% | -0.030 pp | -0.016 pp | -13.7% | No |
| Incyte → INCY | United States | $15.7bn | 0.056% | -0.004 pp | -0.000 pp | -7.9% | No |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.